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Abstract
Background: Various gene-expression signatures for breast cancer are available for the prediction of clinical
outcome. However due to small overlap between different signatures, it is challenging to integrate existing disjoint
signatures to provide a unified insight on the association between gene expression and clinical outcome.
Results: In this paper, we propose a method to integrate different breast cancer gene signatures by using graph
centrality in a context-constrained protein interaction network (PIN). The context-constrained PIN for breast cancer
is built by integrating complete PIN and various gene signatures reported in literatures. Then, we use graph
centralities to quantify the importance of genes to breast cancer. Finally, we get reliable gene signatures that are
consisted by the genes with high graph centrality. The genes which are well-known breast cancer genes, such as
TP53 and BRCA1, are ranked extremely high in our results. Compared with previous results by functional
enrichment analysis, graph centralities, especially the eigenvector centrality and subgraph centrality, based gene
signatures are more tightly related to breast cancer. We validate these signatures on genome-wide microarray
dataset and found strong association between the expression of these signature genes and pathologic parameters.
Conclusions: In summary, graph centralities provide a novel way to connect different cancer signatures and to
understand the mechanism of relationship between gene expression and clinical outcome of breast cancer.
Moreover, this method is not only can be used on breast cancer, but also can be used on other gene expression
related diseases and drug studies.
Background
A gene signature is a group of genes whose expression
pattern represents the status of a gene expression dis-
ease [1]. By using the microarray technology, which
has developed rapidly in last ten years, various gene
signatures are developed for various complex diseases,
especially the cancer. Since researchers found that
gene-expression signatures are able to predict clinical
outcome of breast cancer in 2002 [2,3], it have become
a hot topic and attracted the attention of both biolo-
gists and oncologists. Signatures for various pheno-
types, such as poor prognosis [3], invasiveness [4],
recurrence [5], and metastasis [6,7], have been experi-
mentally derived from patient groups and biological
hypotheses. However, distinct signatures share very few
genes, even though they paradoxically occupy a com-
mon prognosis space. For both cancer biologists and
oncologists, a critical problem is whether these disjoint
genetic signatures can provide a unified insight on the
relationship between gene expression and clinical
outcome.
Obviously, complex heterogeneity of signatures caused
by different probe design, different platforms, or inade-
quate patient samples, becomes an obstacle when trying
to integrate various signatures of breast cancer. Gene
Ontology enrichment, pathway analysis, and some gen-
ome-scale methods are proposed to explain the lack of
overlap [8-10]. In literature [8], the authors list five
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possible explanations for the small overlap between sig-
natures:
1. Heterogeneity in expression due to different plat-
form technologies and references;
2. Differences in supervised protocols with which
signatures are extracted;
3. Although the genes are not exactly the same, they
represent the same set of pathways;
4. Differences in clinical composition between data-
sets (i.e. sample heterogeneity);
5. Small sample size problems that cause inaccurate
signatures.
Through a large-scale analysis that performed on 947
breast cancer samples from Affymetrix platform, the
authors of literature [8] conclude that the small signa-
ture overlap is most likely due to small sample size pro-
blem (explanation 5). However, the conclusion might be
specific to the datasets and the specific techniques used
in their work. By comparison of three prognostic gene
expression signatures for breast cancer, literature [9]
suggested that the small overlap between the different
prognostic gene signatures is because these different sig-
natures represented largely overlapping biological pro-
cesses (explanation 3). By taking into account the
biological knowledge that exists among different signa-
tures, the authors of [10] found that different signatures
are similar at biological level, rather than gene level
(explanation 3). Much work has been done in an effort
to understand the small overlap between gene signa-
tures, but so far there is no widely accepted explanation.
Meanwhile, computational biologists have developed
Protein Interaction Networks(PIN) that effectively have
been used to analyze protein interactions underpinning
share sub-phenotypes among otherwise seemingly dispa-
rate disease, such as retinitis pigmentosa, epithelial ovar-
ian cancer, inflammatory bowel disease, amyotrophic
lateral sclerosis, Alzheimer disease, type 2 diabetes, cor-
onary heart disease [11] and head and neck tumor
metastasis [12]. For an individual expression signature
in breast cancer, protein interaction networks are suc-
cessfully used to predict prognosis [13] and detect sub-
network signatures of metastatic disease [4]. More
recently, in [14], on genome-wide coexpression net-
works for different disease states, the authors used uni-
variate Cox model and Relief algorithm to select the
genes that are the most predictive of clinical outcome to
construct gene signature for lung cancer. A 13-gene
lung cancer prognosis signature with significant prog-
nostic stratifications is identified by this method. By Sin-
gle Protein Analysis of Net-works(SPAN [12]) and
conservative permutation re-sampling, a small, but more
biological significant breast cancer signature consisted
by 54 genes is identified from a protein interaction net-
work include 250 cancer-related genes curated from lit-
eratures [15,16]. In reference [10], by integrating
biological knowledge and different signatures, the
authors derived a unified signature that is more robust
than original signatures.
However, to integrate different breast cancer signa-
tures, most existing methods need cancer domain
knowledge, such as cancer-related literature used in
[10,15,16]. This limited the application of these meth-
ods. In this paper, we describe a method to integrate
different breast cancer signatures by using graph cen-
trality in a context-constrained PIN for human breast
cancer which is constructed by integrating disjoint gene
signatures reported in previous literatures. Unlike most
existing methods, the method proposed in this paper is
able to integrate distinct gene signatures without cancer
domain knowledge. By Gene Ontology (GO) enrichment
analysis, Kyoto Encyclopedia of Genes and Genomes
(KEGG) enrichment analysis and relating our results to
previous biological studies, we show that the genes in
centrality-based signatures are tightly related to breast
cancer and are able to predict clinical outcome.
Methods
To identify reliable gene signature of breast cancer by
integrating various gene signatures, we propose a graph
centrality based method to identify disease genes from a
constrained PIN and the overview of this method is pro-
vided in Figure 1. Briefly, as shown in Figure 1, the
method proposed here has three steps:
1. Collect genes from different breast cancer gene
signatures, and discard the genes that exist in only
one signature.
2. Project the genes collected in Step 1. to human
PIN to construct a context-constrained PIN that
consisted. Therefore, to some extent, all genes in
this context-constrained network are related to
breast cancer. However, we don’t know which genes
are the most important ones to the breast cancer
and can be used to predict clinical outcome.
3. To determine the relationship between genes and
breast cancer, we calculated graph centrality of each
gene in this constrained PIN. Since the constrained
PIN is built based on breast cancer gene signatures,
graph centrality of genes in this network indicates
their relationship to breast cancer. Output given
number of genes with highest graph centrality as the
new unified breast cancer signature.
Details of the three steps are described in following
three subsections and then validation methods are
presented.
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Collecting genes from different signatures
GeneSignDB (http://compbio.dfci.harvard.edu/gene-
sigdb/) [17] is a curated gene signatures database that
collected gene signatures for various species and dis-
eases. Keywords “breast cancer” for disease and
“human” for species are used to search gene signatures
for human breast cancer in GeneSignDB. 94 distinct
human breast cancer signatures are obtained, which
are reported in 58 different literatures. Since the genes
which are included in only one gene signature may be
generated by chance, we discard these unreliable
genes.
Construction of context-constrained PIN
A complete human PIN is constructed by integrating
protein interaction data from Human Protein Reference
Database (HPRD) and BioGRID interaction database
[18,19]. After removal of duplicate edges and self-
interactions, we got a PIN that is consisted by 51057
distinct interactions among 11465 proteins.
Then, the genes we collected in the first step are pro-
jected to the complete human PIN and a constrained
PIN for human breast cancer is obtained. This con-
strained PIN contains 2924 proteins and 4698
interactions.
Use graph centrality to quantify the relationship between
genes and breast cancer
Various definitions of graph centrality have been pro-
posed from different perspectives to evaluate the impor-
tance of nodes in a graph. The concept has been widely
used in bioinformatics, such as discovery of essential
proteins in protein networks [20]. Because it is difficult
to infer which definition is best for identifying disease
genes in the context-constrained network, we evaluated
six different definitions in our work.
Figure 1 Schematic overview of graph centrality based integration of gene signatures. Schematic overview of graph centrality based
integration of distinct breast cancer gene signatures.
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For a protein interaction network G(V,E), the six mea-
surements of centrality used in this study are defined as
following:
• Degree centrality(DC): The degree centrality DC(i)
of vertex i is the number of edges connecting node i
and its neighbors [21].
DC(i) = Deg(i), (1)
where Deg(i) is the degree of vertexes i.
• Betweenness centrality(BC): The betweenness cen-
trality BC(i) of a node i is the average fraction of
shortest paths that pass through the node i [22].
BC(i) =
∑
s
∑
t
σst(i)
σst
, s = t = i, (2)
where sst denotes the total number of shortest paths
between s and t and sst(i) denotes the number of
shortest paths from s to t that pass through the
node i.
• Closeness centrality(CC): The closeness centrality
CC of node i can defined as [23]:
CC(i) =
1∑
j=i cp(i, j)
(3)
CC is a global metric which describes how the given
node i connects to other nodes.
• Subgraph centrality(SC): The subgraph centrality
SC(i) of node i can be defined as [24]:
SC =
∞∑
l=0
μl(i)
l!
, (4)
where μl(i) denotes the number of closed walks of
length l which starts and ends at node i.
• Eigenvector centrality(EC): The eigenvector cen-
trality EC(i) of node i is defined as the ith compo-
nent of the principal eigenvector of A, where A is an
adjacent matrix. Let l be an eigenvalue and e be the
eigenvector. Then for an equation le = Ae, we can
obtain EC(i) = e1(i), where e1 corresponds to the lar-
gest eigenvalue of A [25].
• Information centrality(IC): The information cen-
trality IC(i) of node i in a is defined as [26]:
IC(i) = [
1
n
∑
j
1
Iij
]−1, (5)
where n is the number of nodes in graph G and Iij =
(rii + rjj - rij) - 1, where rij is the element of matrix R.
Let D be a diagonal matrix of the weighted degree of
each node and J be a matrix with all its elements equal
to one. Then, we get R = (rij) = [D - A+ J] - 1. For com-
putational purposes, Iii is defined as infinite. Thus,
1
Iii
= 0.
High centrality of a gene indicates that it is important
to the constrained PIN and probably plays an important
role in mechanism of breast cancer development. There-
fore, according to the graph centrality of genes, we get a
gene list that is ordered by the genes’ importance to
human breast cancer. Depending on specific purpose, a
given number of top genes can be selected to construct
a reliable gene signature of breast cancer. The reliable
gene signature is the integration of the disjoint original
signatures.
KEGG pathway and Gene Ontology enrichment analysis
p-value based on the hypergenometirc distribution is
widely used as a measurement of the extent to which
the clusters are annotated by a specific GO term
[27-30]. Basically, the p-value is defined as following:
P = 1 −
k−1∑
i=0
(
C
i
)(
G − C
n − i
)
(
G
n
) , (6)
where C is the size of the gene set containing k gene
with a given GO term; G is the size of the universal set
of known genes and contains n genes with the
annotation.
Low P in Formula 6 indicates that the module closely
corresponds to the GO annotation because the network
has a rare chance to produce the module. To simplify
our analysis, we define p-score as the negative of log(P)
with the annotation [31].
Gene set enrichment analysis for KEGG pathways is
very similar to the one for GO annotations. In Equation
6, C is the size of the gene set containing k genes that
exist in a given KEGG pathway; G is the size of the uni-
versal set of known genes and contains n genes that
exist in the pathway. Similarly, p-score can be used to
measure the relationship between the gene set and a
specific KEGG pathway.
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In this study, both KEGG and GO enrichment analysis
are performed on DAVID [32].
Validate on microarray dataset
To evaluate the signature’s ability to predict clincal out-
come, we used expression intensity of the genes in the
signature to cluster microarray datasets of breast cancer
patients with different pathologic parameters. Patients
with similar pathologic parameters should be clustered
togather. For a given pathologic parameter, the p-value
of the clustering result indicates the signature’s ability to
predict the pathologic parameter.
In this study, euclidean distance between samples are
calculated by using the expression intensity of genes in
gene signature. Then hierarchical clustering is used to
cluster the microarry datasets of breast cancer patients.
Results
Overlap among breast cancer signatures
As mentioned in Methods section, 94 breast cancer gene
signatures are obtained from public database. Since the
different generation methods and the various purposes
of these signatures, the size of these signatures are very
different. The biggest signature contains 3260 genes,
and the smallest signature only contains 4 genes. The
median size of these signatures is 46.
To evaluate the similarity among these gene signa-
tures, we analyze the overlap among the 94 gene signa-
tures (see Table 1). The analysis result is very consistent
with the results reported in literature [15]. A very small
overlap is found among different signatures. 4143
(58.6% of the total number) genes are found in only one
signature, but only 24(0.4%) genes overlapped 10 or
more signatures, and none of the genes overlapped all
94 signatures. The lack of overlapping is an obstacle to
integrate various signatures of breast cancer.
Centrality based gene signatures
All genes included in the 94 signatures are projected to
the human PIN described in Methods section. In con-
sideration of the lower reliability of gene signatures,
only the genes that are included in two or more differ-
ent signatures are used to construct the context-con-
strained PIN of breast cancer. Finally, this context-
constrained PIN contains 2924 proteins and 4698
interactions.
Then, six graph centralities of each genes in this con-
text-constrained PIN are calculated. Higher centrality
for a gene indicates that the gene is more important to
this network and should be more tightly related to
breast cancer. Graph centrality of each gene in the con-
text-constrained PIN is calculated and provided in Addi-
tional File 1. In a recent similar study performed by
Chen et.al, based on a context-constrained network that
obtained from literatures, 10 published gene signatures
are integrated and a 54-genes signature is obtained [15].
This result is named as “Chen’s signature” in the rest of
this paper. For comparison, we also select 54 most
important genes identified by each centrality definitions
to construct gene signatures. Full list of genes in these
graph centrality based signatures are provided in Table
2.
Since all the six graph centrality definitions are designed
to measure the importance of a node to a graph, gene
signatures identified by the six centrality measurements
are similar with each other. A extremely case is all the
top 54 genes identified by EC and SC are the same. By
contrast, overlap between our results and Chen’s gene
signature is only 5-8(9.3%-14.8%, p-value < 0.05).
An interesting result is found in our work. No matter
which centrality measurement is used to evaluate the
importance of genes in the context-constrained network,
TP53 gene, which is already known as a tumor suppres-
sor, is always the most important gene. Another similar
example is breast cancer type 1 susceptibility protein
(BRCA1). As we expected, our result also shows that
BRCA1 plays an important role in the breast cancer.
Other similar examples include epidermal growth factor
receptor (EGFR), E1A binding protein p300(E300),
Androgen receptor gene(AR) and so on (see Table 2).
However, another well-known breast cancer gene,
BRCA2, is not included in any signature identified by
the six centrality measurement. This is because BRCA2
is included in only one original signature and was dis-
carded when we constructed the context-constrained
PIN. On the one hand, the absence of BRCA2 is also a
evidence to prove that the quality of existing breast can-
cer gene signatures is low, and on the other hand, the
absence of BRCA2 in out signature indicates that our
method can be improved by refining the signature genes
collection method.
Relationship among genes in gene signatures
To investigate the relationship among genes in the gene
signatures, seven sub PINs are constructed by projecting
genes in each gene signature to the complete human
Table 1 Overlap among 94 breast cancer gene signatures
Frequency 1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17
Num of genes 4143 1608 687 323 148 56 40 23 15 13 4 3 1 1 1 1
There is very small overlap among distinct breast cancer signatures. Most genes exist in only one signature, and only 24 genes are included in 10 or more
signatures.
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PIN. As shown in Table 3, the sub PINs consisted by
the genes in the graph centrality based gene signatures
are much denser than that consisted by the genes in
Chen’s signature. We also can observe the significant
difference in Figure 2. The most dense networks are
consisted by the disease genes that are identified by EC
and SC.
KEGG pathways enrichment analysis
As shown in Table 4, the most significant KEGG path-
way of all six graph centrality-based gene signatures are
“pathways in cancer”, but that of Chen’s gene signature
is “Cell cycle”. Chen’s gene signature is also annotated
by “pathways in cancer”, but the p-score is very low. It
is obvious that graph centrality based method is more
powerful than SPAN to identify cancer related genes in
a constrained PIN.
GO enrichment analysis
Biological process GO enrichment analysis is performed
on each gene signatures (see Table 5). For each signa-
ture, the GO biological process with highest p-score and
corresponding p-score are presented in Table 5. Unlike
the genes identified in Chen’s study [15], which is anno-
tated by term “cell cycle”, five centrality-based gene sig-
natures are annotated by “positive regulation of
macromolecule metabolic process” and only the gene
signature identified by BC is annotated by “response to
organic substance”.
Table 2 Graph centrality based breast cancer signatures
BC CC DC EC IC SC
TP53 TP53 TP53 TP53 TP53 TP53
EGFR ESR1 EGFR ESR1 EGFR ESR1
CTNNB1 AR EP300 EP300 EP300 EP300
SMAD3 EGFR ESR1 AR ESR1 AR
ESR1 EP300 BRCA1 BRCA1 BRCA1 BRCA1
EP300 SMAD3 CREBBP CREBBP CREBBP CREBBP
SRC BRCA1 SMAD3 SMAD3 AR SMAD3
BRCA1 CTNNB1 AR EGFR SMAD3 EGFR
CREBBP SRC CTNNB1 HDAC1 SRC HDAC1
AR CREBBP SRC STAT3 CTNNB1 STAT3
UBE2I AKT1 HDAC1 RB1 HDAC1 RB1
DYNLL1 HDAC1 CASP3 CTNNB1 RB1 CTNNB1
CASP3 STAT3 RB1 JUN PIK3R1 JUN
ACTB STAT1 PIK3R1 SRC CASP3 SRC
AKT1 XRCC6 STAT3 AKT1 STAT3 AKT1
HDAC1 RB1 UBE2I SMARCA4 AKT1 SMARCA4
PIK3R1 PIK3R1 AKT1 CDKN1A SHC1 CDKN1A
ZBTB16 PML CDK2 PML CDK2 PML
ACVR1 UBE2I PCNA STAT1 JUN STAT1
RB1 HSPA8 SHC1 CDK2 STAT1 CDK2
STAT1 CASP3 JUN NCOA6 UBE2I NCOA6
HGS CDK2 DYNLL1 HDAC2 CDKN1A HDAC2
CDK2 SMARCA4 STAT1 PIK3R1 PCNA PIK3R1
YWHAZ CDKN1A ACTB UBE2I HDAC2 UBE2I
BCL2 JUN CDKN1A XRCC6 SMARCA4 XRCC6
XRCC6 CDH1 MAPK14 HIF1A NFKB1 HIF1A
STAT3 YWHAZ YWHAZ NFKB1 CDH1 NFKB1
PLK1 MAPK14 BCL2 CASP3 ACTB CASP3
PCNA PRKDC HDAC2 E2F1 MAPK14 E2F1
HSPA8 HIF1A ATM CEBPB LYN CEBPB
FN1 SHC1 LYN PRKDC XRCC6 PRKDC
VIM STUB1 NFKB1 SHC1 ATM SHC1
CD44 HDAC2 XRCC6 NCOA2 ZBTB16 NCOA2
MAPK14 ERBB2 CDH1 CCND1 E2F1 CCND1
GNB2L1 HSPA4 SMARCA4 PCNA YWHAZ PCNA
FANCA BCL2 EZR TDG BCL2 TDG
EEF1A1 ZBTB16 HGS ERBB2 PML ERBB2
SKIL LYN ZBTB16 HSPA4 JAK1 HSPA4
SHC1 NCOA6 PLK1 ZBTB16 EZR ZBTB16
USP7 PAK1 CAV1 RXRA PRKDC RXRA
CAV1 MDM4 E2F1 MAPK14 JAK2 MAPK14
JUN CASP8 JAK1 JAK2 CASP8 JAK2
RXRA CEBPB RXRA STUB1 RXRA STUB1
LYN NFKB1 FN1 CDK7 ERBB2 CDK7
CDKN1A JAK2 HSPA8 PTPN6 HIF1A PTPN6
HIF1A PTPN6 VAV1 ATM CAV1 ATM
ATM HGS ACVR1 BCL3 HSPA8 BCL3
EZR EZR CASP8 DDX5 VAV1 DDX5
PPP1CA CAV1 HIF1A RBL1 CDKN2A RBL1
PAK1 PIAS4 JAK2 FOS NCOA6 FOS
PLSCR1 TDG PML CDH1 PTPN6 CDH1
Table 3 Topological size of context-constrained PINs.
Proteins Interactions
BC 54 238
CC 54 330
DC 54 279
EC 54 352
IC 54 312
SC 54 352
Chen 54(35) 70
To investigate the differences between graph centrality based gene signatures
and that reported in previous literature, topological size of sub-network
consisted by the genes in these gene signatures are calculated and presented
in this table. It should be note that the sub-network consisted by the genes
included in Chen’s gene signature is not a connected graph. The number in
parenthesis is the number of proteins of its biggest connected component.
Table 2 Graph centrality based breast cancer signatures
(Continued)
TGFBR2 IGF1R CDKN2A MDM4 DYNLL1 MDM4
AURKA DDX5 EEF1A1 ING1 HGS ING1
KPNB1 MET ERBB2 SIN3A SIN3A SIN3A
54 genes with highest graph centrality in the context-constrained PIN are
selected to consist new breast cancer gene signatures. The genes in the six
signatures identified by six graph centrality measurements are listed in this table.
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The structure of GO terms is a tree-like structure (see
Figure 3. The term “regulation of biological regulation”,
which is located at the same level of “cell cycle”, is the
ancestor of “positive regulation of macromolecule meta-
bolic process”. According to G2SBC database [33], only
190 breast cancer genes are annotated by “Cell Cycle”,
but 1159 breast cancer genes are annotated by “regula-
tion of biological process”. This indicates that the gene
signatures identified by graph centrality are probably
more tightly related to breast cancer.
According to the p-score, both the two types of
enrichment analysis suggested that EC and SC are prob-
ably the best choices to identify disease genes from con-
text-constrained network and integrate different gene
signatures. As reported in literatures, SC also has super-
ior performance in the discovery of essential proteins in
protein interaction network [34] and essential proteins
tend to have higher correlation with dominant and
recessive mutants of disease genes [35]. This is possibly
the reason that SC and EC outperformed other central-
ity measurements. We also note that the PINs that are
consisted by the disease genes identified by EC and SC
are denser than that of other centrality measurements
(see Table 3). This indicates that breast cancer genes
have tight and complicated relationship with each other.
Validate of the prognostic potential of the subgraph
centrality based gene signature
Since SC and EC outperform in functional enrichment
analysis, we tested the SC and EC based gene signatures
in a genome-wide microarray dataset: GSE7390 [36].
This microarray dataset is downloaded from NCBI GEO
Figure 2 Sub-networks consisted by the genes of different signatures. The first six sub-networks are consisted by the signature genes
identified by six graph centrality measurements, repectively. The last one is consisted by the signature genes identified by Chen. Compared with
Chen’s result, all the sub-networks that consisted by the genes of the signatures that identified by graph centrality are connected graph and
denser.
Table 4 KEGG pathways enrichment analysis results.
Method KEGG Pathway Description Annotated Genes Corrected p-score
BC hsa05200 pathways in cancer 23 13.09
CC hsa05200 pathways in cancer 29 18.92
DC hsa05200 pathways in cancer 31 21.59
EC hsa05200 pathways in cancer 28 25.74
IC hsa05200 pathways in cancer 30 20.22
SC hsa05200 pathways in cancer 28 25.74
Chen hsa04110 Cell cycle 25 26.80
Chen hsa05200 pathways in cancer 11 2.59
To investigate the relationship between the gene signatures and cancer-related pathways, KEGG pathway enrichment analysis is preformed on these signatures.
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database and includes 198 breast cancer patients width
different pre-diagnosed pathologic parameters.
We analyze the relationship between the SC based sig-
nature genes and hormone receptor status using hier-
archical clustering. The 198 patients in GSE7390 were
divided into two main clusters (Additional File 2), the
first cluster includes 118 samples, and the second cluster
includes 80 samples. The mean value of each attribute
of the samples in each cluster are listed in Table 6. As
shown in Table 6, the tumor size and NPI Score of the
Table 5 Gene Ontology enrichment analysis results.
Method GO Term Description p-score
BC GO:0010033 response to organic substance 21.44
CC GO:0010604 positive regulation of macromolecule metabolic process 21.44
DC GO:0010604 positive regulation of macromolecule metabolic process 17.50
EC GO:0010604 positive regulation of macromolecule metabolic process 25.74
IC GO:0010033 response to organic substance 19.60
SC GO:0010604 positive regulation of macromolecule metabolic process 25.74
Chen GO:0007049 cell cycle 19.94
To investigate the relationship between the gene signatures and cancer-related biological processes, Gene Ontology enrichment analysis is preformed on these
signatures.
Figure 3 Relationship among most significant GO terms annotate to significant breast cancer genes identified by different methods.
Relationship among most significant GO terms annotate to significant breast cancer genes identified by different methods. Green boxes
indicates the GO terms annotate to genes identified by centrality, and red box indicate the GO term annotate to Chen’s results.
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first cluster is smaller than those of the second cluster.
Disease-free survival time, overall survival time, distant
metastasis-free survival time, 10-year overall survival
probability and time to distant metastasis of the patients
in the first cluster is longer than those of the patients in
the second cluster. In another word, the condition of
patients in the first cluster is much better than the sec-
ond cluster of patients.
In the first cluster of patients, 104 of them were ER+;
and in the second cluster of patients, only 30 of them
were ER+. The p-value calculated by ANOVA is 2.47 ×
10-13. We also explored the relationship between the
signature genes and the time to distant metastasis. In
the first cluster, the time to distant metastasis of 97
patients were longer than 2000 days; and in the second
cluster, that number is only 55. The p-value is 0.04254.
Normally, p-value that smaller than 0.05 means the
result is statistic significant and is not generated by
chance. Such small p-value of the clustering result indi-
cates that the SC based signature is able to predict the
clinical outcome very well.
Discussion and conclusion
Identification of genes which play important roles in the
development of cancer is a critical problem needed to
solve in current research of various cancers. Gene
expression signatures provide a way to find significant
cancer genes in given groups of patients. Due to the low
overlap between heterogeneous signatures, how to inte-
grate them is becoming a serious problem. Fortunately,
as shown in this paper, graph centralities, especially EC
and SC, are useful tools to integrate existing different
cancer gene signatures.
As well-known, weighted protein interaction network
can be constructed by integrating functional annota-
tions, and centrality is also can be extended to weighted
network easily [20]. More promising results should be
found in the weighted protein interaction network.
Besides this, other topological parameters from graph
theory may improve this method as well.
Additional material
Additional file 1: Graph centrality of genes in the context-
constrained PIN. In this study, graph centrality of each gene in the
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relationship between genes and the breast cancer. The calculation results
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Additional file 2: SC-based gene signature based hierarchical
clustering analysis of breast cancer microarray dataset by using SC-
based gene signature. According to the gene signature identified by
SC, hierarchical clustering analysis is performed on the breast cancer
microarray dataset, GSE7390, which include 198 breast cancer patients
with various pathologic parameters.
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